跳到正文
原文
STAT 主站· Jason Mast·· 2026-10-05AI 评分60

Vaxcyte肺炎球菌疫苗VAX-31 III期试验达到主要终点

STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market

AI 导读

Vaxcyte周一表示其实验性肺炎球菌疫苗VAX-31在III期临床试验中达到主要终点。试验纳入3500余名50岁及以上成年人,随机接受VAX-31、辉瑞Prevnar或默沙东Capvaxive,研究人员测量了针对不同血清型的抗体应答强度。VAX-31设计用于保护31个血清型,Prevnar覆盖20个,Capvaxive覆盖21个。

正文

By Jason Mast

Oct. 5, 2026

General Assignment Reporter

Vaxcyte said Monday that its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the California-based biotech to compete with Pfizer and Merck.

Vaxcyte’s shot, VAX-31, is designed to protect against 31 serotypes, or strains, of bacteria that can cause pneumococcal disease, including pneumonia, compared to 20 strains for Pfizer’s Prevnar and 21 strains for Merck’s Capvaxive.

In the trial, just over 3,500 adults age 50 and older were randomized to receive VAX-31, Prevnar, or Capvaxive. Investigators then measured the strength of their antibody responses against different strains. 

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT 主站 · statnews.com